• DOI:10.1016/S0140-6736(10)61381-5
Corpus ID: 28834830

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

@article{Hallek2010AdditionOR,
  title={Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial},
  author={M. Hallek and K. Fischer and G. Fingerle-Rowson and A. Fink and the German Chronic Lymphocytic Leukaemia Study Group},
  journal={The Lancet},
  year={2010},
  volume={376},
  pages={1164-1174}
}

M. Hallek, K. Fischer, +2 authors the German Chronic Lymphocytic Leukaemia Study Group

Published 2010

Medicine

The Lancet

BACKGROUND On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia. METHODS Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of… CONTINUE READING

View on Elsevier

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed